Quotient Sciences and CPI Launch Joint Venture to Speed Up RNA Drug Development

Quotient Sciences, a global leader in drug development and manufacturing acceleration, has joined forces with UK technology innovation centre CPI to form a joint venture (JV) focused on speeding up the development of RNA-based therapies. The collaboration was announced following the signing of a memorandum of understanding (MoU).

The new JV will integrate Quotient’s Translational Pharmaceutics platform with CPI’s expertise in RNA small-scale manufacturing and lipid nanoparticle (LNP) encapsulation. This combined offering aims to deliver a streamlined, end-to-end solution for the development of mRNA drug products, meeting the increasing demand for faster and more agile RNA therapeutic development.

Thierry Van Nieuwenhove, CEO of Quotient Sciences, highlighted the significance of the partnership, noting that the JV will enable developers to move from plasmid to clinical dose in as little as two months. This rapid supply chain aims to accelerate early-phase clinical trials and improve chances of success by allowing dose and formulation adjustments based on real-time clinical data.

The joint venture will provide integrated services including mRNA synthesis, LNP formulation development, clinical manufacturing, and early-phase clinical testing—all within a collaborative framework. This approach is particularly advantageous for RNA therapies where drug delivery is crucial to effectiveness.

Frank Millar, CEO of CPI, expressed pride in the partnership, emphasizing their shared vision to create scalable and sustainable pathways for mRNA therapy development that address global health challenges.

Quotient’s Translational Pharmaceutics platform, already used in over 500 programs worldwide, will now extend its application to mRNA therapeutics through this JV.

Further details on the joint venture’s name, branding, and operational plans will be disclosed as the collaboration advances.